New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareChonluten vs Dihexa

Chonluten vs Dihexa

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Chonluten
Cognitive Enhancement
Dihexa
Summary
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
Dihexa is a potent experimental oligopeptide derived from angiotensin IV that dramatically enhances synaptogenesis. Preclinical research shows cognitive enhancement orders of magnitude more potent than BDNF — it is considered one of the most powerful nootropic compounds in research, but has very limited human safety data.
Half-Life
Short (minutes for the peptide); sustained gene-regulatory effects
Unknown (limited pharmacokinetic data)
Admin Route
SubQ, Oral
Oral, SubQ, Topical
Research
Typical Dose
10 mg per day
5–10 mg
Frequency
Daily for 10–30 days
Daily
Key Benefits
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
  • Dramatically increases synapse formation (potentially 10 million× more potent than BDNF in animal models)
  • Enhances memory and learning
  • May reverse cognitive decline
  • Improves neuroplasticity and executive function
  • Long-lasting cognitive benefits from short courses
  • Potential therapeutic agent for Alzheimer's
Side Effects
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
  • Headache
  • Irritability
  • Brain fog during washout period
  • Unknown long-term effects (insufficient data)
Stacks With